Discover oncology · 2026
Inflammatory regulation of PD-L1 protein fate in the tumor microenvironment shapes immune escape and therapeutic targeting.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liang Kuan, Jia Ziang, Lu Haiwen, Wang Qianqian, Huang Haihui, Yan Ziling, Wang Yukun, Liu Xia
Аннотация
BACKGROUND: Programmed death-ligand 1 (PD-L1) has traditionally been regarded as a membrane-bound immune checkpoint ligand that suppresses antitumor T-cell activity through PD-1 engagement. Although this framework remains fundamental, it is no longer sufficient to capture the full biologic and clinical complexity of PD-L1 in cancer. Accumulating evidence indicates that PD-L1 is not a static surface marker, but a dynamically regulated molecular hub positioned at the intersection of inflammatory signaling, tumor-cell adaptation, and immune escape.
MAIN BODY: Within the tumor microenvironment, inflammatory cues including interferons, TNF-α, IL-6, Toll-like receptor signaling, hypoxia, and therapy-induced stress regulate PD-L1 through transcriptional, post-transcriptional, and post-translational mechanisms. These inputs do not merely increase PD-L1 abundance. They shape PD-L1 protein fate through glycosylation, ubiquitination, palmitoylation, endocytic trafficking, recycling, and degradation, thereby determining membrane abundance, localization, and activity. Beyond canonical PD-1 ligation, PD-L1 can also exert tumor-intrinsic effects, mediate exosomal immunosuppressive communication, and adopt context-dependent nuclear functions linked to stress adaptation and treatment resistance. In turn, PD-L1 participates in self-reinforcing circuits involving exhausted T cells, myeloid suppressor populations, stromal signaling, additional checkpoint-sensitive immune compartments, and therapy-driven adaptive resistance. We distinguish validated from emerging PD-L1 states across experimental models and human tumors.
CONCLUSION: A framework linking inflammatory input, PD-L1 protein fate, functional output, and feedback provides an integrated view of PD-L1 biology in cancer. Translationally, this framework argues for moving beyond single-point PD-L1 testing toward integrated assessment of inflammatory context, spatial organization, and dynamic PD-L1 states, while supporting mechanism-guided combination strategies targeting the PD-L1 axis.
MAIN BODY: Within the tumor microenvironment, inflammatory cues including interferons, TNF-α, IL-6, Toll-like receptor signaling, hypoxia, and therapy-induced stress regulate PD-L1 through transcriptional, post-transcriptional, and post-translational mechanisms. These inputs do not merely increase PD-L1 abundance. They shape PD-L1 protein fate through glycosylation, ubiquitination, palmitoylation, endocytic trafficking, recycling, and degradation, thereby determining membrane abundance, localization, and activity. Beyond canonical PD-1 ligation, PD-L1 can also exert tumor-intrinsic effects, mediate exosomal immunosuppressive communication, and adopt context-dependent nuclear functions linked to stress adaptation and treatment resistance. In turn, PD-L1 participates in self-reinforcing circuits involving exhausted T cells, myeloid suppressor populations, stromal signaling, additional checkpoint-sensitive immune compartments, and therapy-driven adaptive resistance. We distinguish validated from emerging PD-L1 states across experimental models and human tumors.
CONCLUSION: A framework linking inflammatory input, PD-L1 protein fate, functional output, and feedback provides an integrated view of PD-L1 biology in cancer. Translationally, this framework argues for moving beyond single-point PD-L1 testing toward integrated assessment of inflammatory context, spatial organization, and dynamic PD-L1 states, while supporting mechanism-guided combination strategies targeting the PD-L1 axis.